Gerard Sanacora

Yale New Haven Hospital — United States

Medicine · Health Sciences

85h-index32.9kcitations280works4.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Treatment of Major Depression(175), Tryptophan and brain disorders(112), Neuroscience and Neuropharmacology Research(74), Mental Health Research Topics(36), Functional Brain Connectivity Studies(29)

Publications280 total

Recommendations for the Deprescribing of Psychotropic Medications
JAMA Network Open·2026· 1 citedOpen Access
A novel, experimental design to assess rapid antidepressant action: Results from a phase 1b randomized trial of NV-5138
Journal of Psychiatric Research·2026Open Access
Evaluating a New Addition to the Treatment Toolbox for Major Depressive Disorder
American Journal of Psychiatry·2025· 1 cited
Transdiagnostic connectome-based predictive modeling of many behavioral phenotypes reveals brain network mediators of clinical-cognitive relationships
2025Open Access
Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
American Journal of Psychiatry·2025
Placebo Effects in the Treatment of Depression—Implications for the Psychedelic Renaissance
Neurologic Clinics·2025· 1 cited
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval
American Journal of Psychiatry·2025· 9 cited
Ketamine for Depression, but at What Cost? A Review of Ketamine’s Neurotoxic Effects From Preclinical and Human Studies
American Journal of Psychiatry·2025· 4 cited
Cover Image, Volume 198, Number 7, October 2025
American Journal of Medical Genetics Part B Neuropsychiatric Genetics·2025Open Access
Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression
The Journal of Clinical Psychiatry·2025
Electroconvulsive Therapy vs Ketamine for Treatment-Resistant Depression: A Noninferiority Randomized Trial
2025Open Access
Safety and Efficacy of the NMDA‐2b‐Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder
Clinical Pharmacology & Therapeutics·2025Open Access
A Transdiagnostic fMRI Dataset With 300+ Deeply Phenotyped Subjects Across Resting and Task States
2025· 2 citedOpen Access
Genetics of Response to <scp>ECT</scp>, <scp>TMS</scp>, Ketamine and Esketamine
American Journal of Medical Genetics Part B Neuropsychiatric Genetics·2025· 1 citedOpen Access
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
The International Journal of Neuropsychopharmacology·2025· 17 citedOpen Access
Developing algorithmic psychiatry via multi-level spanning computational models
Cell Reports Medicine·2025· 3 citedOpen Access
Issues in Clinical Trial Design—Lessons From the FDA’s Rejection of MDMA
JAMA Psychiatry·2025· 8 cited
Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians
FOCUS The Journal of Lifelong Learning in Psychiatry·2025
Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis
Psychiatry Research·2025
Strengthening Safeguards for Psychiatric Uses of Ketamine
JAMA Psychiatry·2025· 5 cited
page 1 of 14Next →

Frequent Co-authors

John H. Krystal(20), Ronald S. Duman(10), Graeme F. Mason(7), James W. Murrough(7), Husseini K. Manji(6), Douglas L. Rothman(5), Pilar Lim(5), Wayne C. Drevets(5), Samuel T. Wilkinson(5), Sanjay J. Mathew(5), Dennis S. Charney(5), Carlos A. Zarate(4), Jaskaran Singh(4), Rosanne Lane(4), David Hough(4), Charles B. Nemeroff(4), Robert Berman(4), Chadi G. Abdallah(4), Dan V. Iosifescu(3), Siegfried Kasper(3)